BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22234091)

  • 1. Frequency of Ki-67 (MIB-1) and P53 expressions among patients with prostate cancer.
    Madani SH; Ameli S; Khazaei S; Kanani M; Izadi B
    Indian J Pathol Microbiol; 2011; 54(4):688-91. PubMed ID: 22234091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of p53 and ki-67 expression in prostate cancer.
    Verma R; Gupta V; Singh J; Verma M; Gupta G; Gupta S; Sen R; Ralli M
    Urol Ann; 2015; 7(4):488-93. PubMed ID: 26692671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
    Sasor A; Wagrowska-Danilewicz M; Danilewicz M
    Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship of the histologic grade at the deep invasive front and the expression of Ki-67 antigen and p53 protein in oral squamous cell carcinoma.
    Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Tomoyose T; Takano H; Funaki K; Fukuyama H; Takahashi T; Sakoda S
    J Oral Pathol Med; 2005 Nov; 34(10):602-7. PubMed ID: 16202080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in prostate cancer.
    Stattin P
    Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
    Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder.
    Shrestha ML; Miyake H; Kikutsuji T; Tashiro S
    J Med Invest; 1998 Aug; 45(1-4):95-102. PubMed ID: 9864969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
    Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
    Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of repeated biopsies in prognosis of prostate cancer].
    Romics I; Lovász S; Szabó J; Szomor L; Minik K; Bartók K; Kerényi T; Szende B
    Orv Hetil; 2002 Jul; 143(27):1619-23. PubMed ID: 12179998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunohistochemical study of p53 and Ki-67 antigen expression in bladder carcinoma].
    Yuge F; Hirakata H; Igarashi H; Kodama M; Kawata N; Takimoto Y
    Hinyokika Kiyo; 1999 Jul; 45(7):453-6. PubMed ID: 10466059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cell proliferation and survival in patients with prostate cancer followed expectantly.
    Borre M; Bentzen SM; Nerstrøm B; Overgaard J
    J Urol; 1998 May; 159(5):1609-14. PubMed ID: 9554364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
    Sakai K; Hongo K; Tanaka Y; Nakayama J
    Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
    Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
    Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki-67, p53 and bcl-2 analysis in colonic versus rectal adenocarcinoma.
    Petrişor O; Giuşcă SE; Sajin M; Dobrescu G; Căruntu ID
    Rom J Morphol Embryol; 2008; 49(2):163-71. PubMed ID: 18516322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer.
    Papadopoulos I; Rudolph P; Wirth B; Weichert-Jacobsen K
    Urology; 1996 Aug; 48(2):261-8. PubMed ID: 8753738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutated p53 protein expression and proliferative activity in advanced gastric cancer.
    Ikeguchi M; Saito H; Kondo A; Tsujitani S; Maeta M; Kaibara N
    Hepatogastroenterology; 1999; 46(28):2648-53. PubMed ID: 10522058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
    Kleer CG; Giordano TJ; Braun T; Oberman HA
    Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.